Table Info

Table 3.

miRNA markers for MG diagnosis

EOMG	TAMG	MuSK+ MG	AChR+ MG	LOMG
Down-regulation: miR-7-5p, miR-29, miR-548k, miR-145, miR-24, and miR-143, miR-146	Up-regulation: let-7a-5p, let-7f-5p, miR-125a-5p	Down-regulation: miR-210-3p, miR-324-3p	Down-regulation: miR-15b, miR-122, miR-140-3p, miR-185, miR-192, miR-20b, and miR-885-5p, miR-27a-3p	Up-regulation: miR-30e-5p, miR-150-5p, miR-21-5p, miR-106b-3p, miR-223-5p, miR-140-5p, miR-19b-3p
Up-regulation: miR-150-5p, miR-21-5p	Up-regulation: let-7a-5p, let-7f-5p, miR-125a-5p	Up-regulation: miR-151a-3p, let-7f-5p, let-7a-5p, miR-423-5p	Up-regulation: miR-150-5p and miR-21-5p	-
Up-regulation in PBMCs: miR-612, miR-3654, miR-3651, and precursor miR-3651	-	-	-	-

PMBC: peripheral blood mononuclear blood cell; -: blank cells

Declarations

Author contributions

FA: Conceptualization, Writing—immunologic, gut microbiome, and other biomarkers section. RR: Conceptualization, Writing—genetic factors and miRNA biomarkers section. Both of the authors contributed to manuscript revision, read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Lazaridis K, Tzartos SJ. Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics. Front Immunol. 2020;11:212. [DOI] [PubMed] [PMC]

Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010;10:46. [DOI] [PubMed] [PMC]

Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14:1023–36. [DOI] [PubMed]

Lacazette E, Le Calvez S, Gajendran N, Brenner HR. A novel pathway for MuSK to induce key genes in neuromuscular synapse formation. J Cell Biol. 2003;161:727–36. [DOI] [PubMed] [PMC]

Mantegazza R, Cavalcante P. Diagnosis and treatment of myasthenia gravis. Curr Opin Rheumatol. 2019;31:623–33. [DOI] [PubMed]

Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10:2235. [DOI] [PubMed] [PMC]

Bernard C, Frih H, Pasquet F, Kerever S, Jamilloux Y, Tronc F, et al. Thymoma associated with autoimmune diseases: 85 cases and literature review. Autoimmun Rev. 2016;15:82–92. [DOI] [PubMed]

Vrolix K, Fraussen J, Losen M, Stevens J, Lazaridis K, Molenaar PC, et al. Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor. J Autoimmun. 2014;52:101–12. [DOI] [PubMed]

Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord. 2006;16:459–67. [DOI] [PubMed]

10.

Rødgaard A, Nielsen FC, Djurup R, Somnier F, Gammeltoft S. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin Exp Immunol. 1987;67:82–8. [PubMed] [PMC]

11.

Bartoccioni E, Scuderi F, Minicuci GM, Marino M, Ciaraffa F, Evoli A. Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology. 2006;67:505–7. [DOI] [PubMed]

12.

Strijbos E, Verschuuren JJGM, Kuks JBM. Serum acetylcholine receptor antibodies before the clinical onset of myasthenia gravis. J Neuromuscul Dis. 2018;5:261–4. [DOI] [PubMed]

13.

Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7:365–8. [DOI] [PubMed]

14.

Kawakami Y, Ito M, Hirayama M, Sahashi K, Ohkawara B, Masuda A, et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology. 2011;77:1819–26. [DOI] [PubMed] [PMC]

15.

Huijbers MG, Zhang W, Klooster R, Niks EH, Friese MB, Straasheijm KR, et al. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci U S A. 2013;110:20783–8. [DOI] [PubMed] [PMC]

16.

Evoli A, Bianchi MR, Riso R, Minicuci GM, Batocchi AP, Servidei S, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci. 2008;1132:76–83. [DOI] [PubMed]

17.

Iorio R, Damato V, Alboini PE, Evoli A. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2015;262:1115–9. [DOI] [PubMed]

18.

Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44:36–40. [DOI] [PubMed]

19.

Kim N, Stiegler AL, Cameron TO, Hallock PT, Gomez AM, Huang JH, et al. Lrp4 is a receptor for agrin and forms a complex with MuSK. Cell. 2008;135:334–42. [DOI] [PubMed] [PMC]

20.

Tzartos JS, Zisimopoulou P, Rentzos M, Karandreas N, Zouvelou V, Evangelakou P, et al. LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. Ann Clin Transl Neurol. 2014;1:80–7. [DOI] [PubMed] [PMC]

21.

Tsonis AI, Zisimopoulou P, Lazaridis K, Tzartos J, Matsigkou E, Zouvelou V, et al. MuSK autoantibodies in myasthenia gravis detected by cell based assay--a multinational study. J Neuroimmunol. 2015;284:10–7. [DOI] [PubMed]

22.

Cordts I, Bodart N, Hartmann K, Karagiorgou K, Tzartos JS, Mei L, et al. Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis. J Neurol. 2017;264:1193–203. [DOI] [PubMed]

23.

Skeie GO, Mygland A, Treves S, Gilhus NE, Aarli JA, Zorzato F. Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro. Muscle Nerve. 2003;27:81–9. [DOI] [PubMed]

24.

Kellermayer D, Smith JE 3rd, Granzier H. Titin mutations and muscle disease. Pflugers Arch. 2019;471:673–82. [DOI] [PubMed] [PMC]

25.

Szczudlik P, Szyluk B, Lipowska M, Ryniewicz B, Kubiszewska J, Dutkiewicz M, et al. Antititin antibody in early- and late-onset myasthenia gravis. Acta Neurol Scand. 2014;130:229–33. [DOI] [PubMed]

26.

Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? Neurology. 2001;57:1579–82. [DOI] [PubMed]

27.

Mygland A, Tysnes OB, Matre R, Volpe P, Aarli JA, Gilhus NE. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Ann Neurol. 1992;32:589–91. [DOI] [PubMed]

28.

Takamori M, Motomura M, Kawaguchi N, Nemoto Y, Hattori T, Yoshikawa H, et al. Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology. 2004;62:1894–6. [DOI] [PubMed]

29.

Stergiou C, Lazaridis K, Zouvelou V, Tzartos J, Mantegazza R, Antozzi C, et al. Titin antibodies in “seronegative” myasthenia gravis--a new role for an old antigen. J Neuroimmunol. 2016;292:108–15. [DOI] [PubMed]

30.

Cossins J, Belaya K, Zoltowska K, Koneczny I, Maxwell S, Jacobson L, et al. The search for new antigenic targets in myasthenia gravis. Ann N Y Acad Sci. 2012;1275:123–8. [DOI] [PubMed]

31.

Suzuki S, Baba A, Kaida K, Utsugisawa K, Kita Y, Tsugawa J, et al. Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies. Eur J Neurol. 2014;21:223–30. [DOI] [PubMed]

32.

Suzuki S, Satoh T, Yasuoka H, Hamaguchi Y, Tanaka K, Kawakami Y, et al. Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis. J Neuroimmunol. 2005;170:141–9. [DOI] [PubMed]

33.

Romi F, Suzuki S, Suzuki N, Petzold A, Plant GT, Gilhus NE. Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis. J Neurol. 2012;259:1312–6. [DOI] [PubMed]

34.

Agius MA, Zhu S, Aarli JA. Antirapsyn antibodies occur commonly in patients with lupus. Ann N Y Acad Sci. 1998;841:525–6. [DOI] [PubMed]

35.

Agius MA, Zhu S, Fairclough RH. Antirapsyn antibodies in chronic procainamide-associated myopathy (CPAM). Ann N Y Acad Sci. 1998;841:527–9. [DOI] [PubMed]

36.

Agius MA, Zhu S, Kirvan CA, Schafer AL, Lin MY, Fairclough RH, et al. Rapsyn antibodies in myasthenia gravis. Ann N Y Acad Sci. 1998;841:516–21. [DOI] [PubMed]

37.

Gallardo E, Martínez-Hernández E, Titulaer MJ, Huijbers MG, Martínez MA, Ramos A, et al. Cortactin autoantibodies in myasthenia gravis. Autoimmun Rev. 2014;13:1003–7. [DOI] [PubMed]

38.

Labrador-Horrillo M, Martínez MA, Selva-O’Callaghan A, Trallero-Araguás E, Grau-Junyent JM, Vilardell-Tarrés M, et al. Identification of a novel myositis-associated antibody directed against cortactin. Autoimmun Rev. 2014;13:1008–12. [DOI] [PubMed]

39.

Illa I, Cortés-Vicente E, Martínez MÁ, Gallardo E. Diagnostic utility of cortactin antibodies in myasthenia gravis. Ann N Y Acad Sci. 2018;1412:90–4. [DOI] [PubMed]

40.

Cortés-Vicente E, Gallardo E, Martínez MÁ, Díaz-Manera J, Querol L, Rojas-García R, et al. Clinical characteristics of patients with double-seronegative myasthenia gravis and antibodies to cortactin. JAMA Neurol. 2016;73:1099–104. [DOI] [PubMed]

41.

Mappouras DG, Philippou G, Haralambous S, Tzartos SJ, Balafas A, Souvatzoglou A, et al. Antibodies to acetylcholinesterase cross-reacting with thyroglobulin in myasthenia gravis and Graves’s disease. Clin Exp Immunol. 1995;100:336–43. [DOI] [PubMed] [PMC]

42.

De Bellis A, Sansone D, Coronella C, Conte M, Iorio S, Perrino S, et al. Serum antibodies to collagen XIII: a further good marker of active Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 2005;62:24–9. [DOI] [PubMed]

43.

Tu H, Pirskanen-Matell R, Heikkinen A, Oikarainen T, Risteli J, Pihlajaniemi T. Autoimmune antibodies to collagen XIII in myasthenia gravis patients. Muscle Nerve. 2018;57:506–10. [DOI] [PubMed]

44.

Zoltowska Katarzyna M, Belaya K, Leite M, Patrick W, Vincent A, Beeson D. Collagen Q--a potential target for autoantibodies in myasthenia gravis. J Neurol Sci. 2015;348:241–4. [DOI] [PubMed] [PMC]

45.

Wen Y, Yang B, Lu J, Zhang J, Yang H, Li J. Imbalance of circulating CD4⁺CXCR5⁺FOXP3⁺ Tfr-like cells and CD4⁺CXCR⁺FOXP3^– Tfh-like cells in myasthenia gravis. Neurosci Lett. 2016;630:176–82. [DOI] [PubMed]

46.

Ma Q, Ran H, Li Y, Lu Y, Liu X, Huang H, et al. Circulating Th1/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients. Clin Immunol. 2020;218:108492. [DOI] [PubMed]

47.

Ingelfinger F, Krishnarajah S, Kramer M, Utz SG, Galli E, Lutz M, et al. Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature. Acta Neuropathol. 2021;141:901–15. Erratum in: Acta Neuropathol. 2021;142:789. [DOI] [PubMed] [PMC]

48.

Simpson TR, Quezada SA, Allison JP. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol. 2010;22:326–32. [DOI] [PubMed]

49.

Zamani MR, Aslani S, Salmaninejad A, Javan MR, Rezaei N. PD-1/PD-L and autoimmunity: a growing relationship. Cell Immunol. 2016;310:27–41. [DOI] [PubMed]

50.

Yan X, Gu Y, Wang C, Sun S, Wang X, Tian J, et al. Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis. Clin Immunol. 2019;207:68–78. [DOI] [PubMed]

51.

Zhang Y, Zhang X, Xia Y, Jia X, Li H, Zhang Y, et al. CD19+ Tim-1+ B cells are decreased and negatively correlated with disease severity in myasthenia gravis patients. Immunol Res. 2016;64:1216–24. [DOI] [PubMed]

52.

Lu J, Li J, Zhu TQ, Zhang L, Wang Y, Tian FF, et al. Modulation of B cell regulatory molecules CD22 and CD72 in myasthenia gravis and multiple sclerosis. Inflammation. 2013;36:521–8. [DOI] [PubMed]

53.

Kakoulidou M, Wang X, Zhao X, Pirskanen R, Lefvert AK. Soluble costimulatory factors sCD28, sCD80, sCD86 and sCD152 in relation to other markers of immune activation in patients with myasthenia gravis. J Neuroimmunol. 2007;185:150–61. [DOI] [PubMed]

54.

Çebi M, Durmus H, Aysal F, Özkan B, Gül GE, Çakar A, et al. CD4⁺ T cells of myasthenia gravis patients are characterized by increased IL-21, IL-4, and IL-17A productions and higher presence of PD-1 and ICOS. Front Immunol. 2020;11:809. [DOI] [PubMed] [PMC]

55.

Yilmaz V, Oflazer P, Aysal F, Durmus H, Poulas K, Yentur SP, et al. Differential cytokine changes in patients with myasthenia gravis with antibodies against AChR and MuSK. PLoS One. 2015;10:e0123546. [DOI] [PubMed] [PMC]

56.

Huan X, Zhao R, Song J, Zhong H, Su M, Yan C, et al. Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis. BMC Immunol. 2022;23:26. [DOI] [PubMed] [PMC]

57.

Jonsson DI, Pirskanen R, Piehl F. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab. Neuromuscul Disord. 2017;27:565–8. [DOI] [PubMed]

58.

Wang Z, Wang W, Chen Y, Xu S, Wei D, Huang X. Elevated expression of interleukin-33 in myasthenia gravis patients. J Clin Neurosci. 2019;63:32–6. [DOI] [PubMed]

59.

Zhang QX, Li Y, Jiang SM, Zhang LJ, Yi M, Wang J, et al. Increased serum IL-36γ levels are associated with disease severity in myasthenia gravis patients. BMC Neurol. 2020;20:307. [DOI] [PubMed] [PMC]

60.

Yi M, Zhang LJ, Liu XJ, Wang N, Huang CN, Liu MQ, et al. Increased serum IL-27 concentrations and IL-27-producing cells in MG patients with positive AChR-Ab. J Clin Neurosci. 2021;86:289–93. [DOI] [PubMed]

61.

Molin CJ, Westerberg E, Punga AR. Profile of upregulated inflammatory proteins in sera of myasthenia gravis patients. Sci Rep. 2017;7:39716. [DOI] [PubMed] [PMC]

62.

Wilf-Yarkoni A, Alkalay Y, Brenner T, Karni A. High κ free light chain is a potential biomarker for double seronegative and ocular myasthenia gravis. Neurol Neuroimmunol Neuroinflamm. 2020;7:e831. [DOI] [PubMed] [PMC]

63.

Cai GM, Gao Z, Yue YX, Xie YC, Gao X, Hao HJ, et al. Association between CTLA-4 gene polymorphism and myasthenia gravis in a Chinese cohort. J Clin Neurosci. 2019;69:31–7. [DOI] [PubMed]

64.

Fang TK, Yan CJ, Du J. CTLA-4 methylation regulates the pathogenesis of myasthenia gravis and the expression of related cytokines. Medicine (Baltimore). 2018;97:e0620. [DOI] [PubMed] [PMC]

65.

Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14:e218–28. [DOI] [PubMed]

66.

Yang HW, Wang YX, Bao J, Wang SH, Lei P, Sun ZL. Correlation of HLA-DQ and TNF-α gene polymorphisms with ocular myasthenia gravis combined with thyroid-associated ophthalmopathy. Biosci Rep. 2017;37:BSR20160440. [DOI] [PubMed] [PMC]

67.

Ling CS, Shen ML, Wang Y, Cai WK, Lin XQ, Huang Q, et al. The associations of HLA-DRB1 gene polymorphisms with late-onset myasthenia gravis: a meta-analysis. Neurol Sci. 2020;41:1041–9. [DOI] [PubMed]

68.

Na SJ, Lee JH, Kim SW, Kim DS, Shon EH, Park HJ, et al. Whole-genome analysis in Korean patients with autoimmune myasthenia gravis. Yonsei Med J. 2014;55:660–8. [DOI] [PubMed] [PMC]

69.

Chia R, Saez-Atienzar S, Murphy N, Chiò A, Blauwendraat C; International Myasthenia Gravis Genomics Consortium; Roda RH, Tienari PJ, Kaminski HJ, Ricciardi R, Guida M, De Rosa A, et al. Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study. Proc Natl Acad Sci U S A. 2022;119:e2108672119. Erratum in: Proc Natl Acad Sci U S A. 2022;119:e2206754119. [DOI] [PubMed] [PMC]

70.

Topaloudi A, Zagoriti Z, Flint AC, Martinez MB, Yang Z, Tsetsos F, et al. Myasthenia gravis genome-wide association study implicates AGRN as a risk locus. J Med Genet. 2022;59:801–9. [DOI] [PubMed]

71.

Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141:1202–7. [DOI] [PubMed] [PMC]

72.

Sabre L, Punga T, Punga AR. Circulating miRNAs as potential biomarkers in myasthenia gravis: tools for personalized medicine. Front Immunol. 2020;11:213. [DOI] [PubMed] [PMC]

73.

Punga T, Le Panse R, Andersson M, Truffault F, Berrih-Aknin S, Punga AR. Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker. Ann Clin Transl Neurol. 2014;1:49–58. [DOI] [PubMed] [PMC]

74.

Smith NL, Wissink EM, Grimson A, Rudd BD. miR-150 regulates differentiation and cytolytic effector function in CD8+ T cells. Sci Rep. 2015;5:16399. [DOI] [PubMed] [PMC]

75.

Fenoglio C, Cantoni C, De Riz M, Ridolfi E, Cortini F, Serpente M, et al. Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. Neurosci Lett. 2011;504:9–12. [DOI] [PubMed]

76.

Garchow BG, Bartulos Encinas O, Leung YT, Tsao PY, Eisenberg RA, Caricchio R, et al. Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice. EMBO Mol Med. 2011;3:605–15. [DOI] [PubMed] [PMC]

77.

Balandina A, Lécart S, Dartevelle P, Saoudi A, Berrih-Aknin S. Functional defect of regulatory CD4⁺CD25⁺ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood. 2005;105:735–41. [DOI] [PubMed] [PMC]

78.

Wang S, Tang Y, Cui H, Zhao X, Luo X, Pan W, et al. Let-7/miR-98 regulate Fas and Fas-mediated apoptosis. Genes Immun. 2011;12:149–54. [DOI] [PubMed]

79.

Lv J, Ren L, Han S, Zhang J, Zhao X, Zhang Y, et al. Peripheral blood hsa-circRNA5333-4: a novel biomarker for myasthenia gravis. Clin Immunol. 2021;224:108676. [DOI] [PubMed]

80.

Ghafouri-Fard S, Azimi T, Hussen BM, Taheri M, Jalili Khoshnoud R. A review on the role of non-coding RNAs in the pathogenesis of myasthenia gravis. Int J Mol Sci. 2021;22:12964. [DOI] [PubMed] [PMC]

81.

Lu W, Lu Y, Wang CF, Chen TT. Expression profiling and bioinformatics analysis of exosomal long noncoding RNAs in patients with myasthenia gravis by RNA sequencing. J Clin Lab Anal. 2021;35:e23722. [DOI] [PubMed] [PMC]

82.

Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654–9. [DOI] [PubMed]

83.

Frank DN, Zhu W, Sartor RB, Li E. Investigating the biological and clinical significance of human dysbioses. Trends Microbiol. 2011;19:427–34. [DOI] [PubMed] [PMC]

84.

Zheng P, Li Y, Wu J, Zhang H, Huang Y, Tan X, et al. Perturbed microbial ecology in myasthenia gravis: evidence from the gut microbiome and fecal metabolome. Adv Sci (Weinh). 2019;6:1901441. Erratum in: Adv Sci (Weinh). 2020;7:2001296. [DOI] [PubMed] [PMC]

85.

Thye AY, Law JW, Tan LT, Thurairajasingam S, Chan KG, Letchumanan V, et al. Exploring the gut microbiome in myasthenia gravis. Nutrients. 2022;14:1647. [DOI] [PubMed] [PMC]

86.

Qiu D, Xia Z, Jiao X, Deng J, Zhang L, Li J. Altered gut microbiota in myasthenia gravis. Front Microbiol. 2018;9:2627. [DOI] [PubMed] [PMC]

87.

Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011;331:337–41. [DOI] [PubMed] [PMC]

88.

Nagano Y, Itoh K, Honda K. The induction of Treg cells by gut-indigenous Clostridium. Curr Opin Immunol. 2012;24:392–7. [DOI] [PubMed]

89.

Moris G, Arboleya S, Mancabelli L, Milani C, Ventura M, de Los Reyes-Gavilán CG, et al. Fecal microbiota profile in a group of myasthenia gravis patients. Sci Rep. 2018;8:14384. [DOI] [PubMed] [PMC]

90.

Choi JM, Bothwell AL. The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases. Mol Cells. 2012;33:217–22. [DOI] [PubMed] [PMC]

91.

Ehrchen JM, Sunderkötter C, Foell D, Vogl T, Roth J. The endogenous toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86:557–66. [DOI] [PubMed]

92.

Halfvarson J, Brislawn CJ, Lamendella R, Vázquez-Baeza Y, Walters WA, Bramer LM, et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol. 2017;2:17004. [DOI] [PubMed] [PMC]

93.

Stascheit F, Hotter B, Hoffmann S, Kohler S, Lehnerer S, Sputtek A, et al. Calprotectin as potential novel biomarker in myasthenia gravis. J Transl Autoimmun. 2021;4:100111. [DOI] [PubMed] [PMC]

94.

Blackmore D, Siddiqi Z, Li L, Wang N, Maksymowych W. Beyond the antibodies: serum metabolomic profiling of myasthenia gravis. Metabolomics. 2019;15:109. [DOI] [PubMed]

95.

Kośliński P, Rzepiński Ł, Koba M, Gackowski M, Maciejek Z. Amino acids levels as a potential biomarker in myasthenia gravis. Folia Neuropathol. 2022;60:122–7. [DOI] [PubMed]

96.

Angelopoulou E, Paudel YN, Piperi C. Unraveling the role of receptor for advanced glycation end products (RAGE) and its ligands in myasthenia gravis. ACS Chem Neurosci. 2020;11:663–73. [DOI] [PubMed]

97.

Mu L, Zhang Y, Sun B, Wang J, Xie X, Li N, et al. Activation of the receptor for advanced glycation end products (RAGE) exacerbates experimental autoimmune myasthenia gravis symptoms. Clin Immunol. 2011;141:36–48. [DOI] [PubMed]

98.

Park KH, Jung J, Lee JH, Hong YH. Blood transcriptome profiling in myasthenia gravis patients to assess disease activity: a pilot RNA-seq study. Exp Neurobiol. 2016;25:40–7. [DOI] [PubMed] [PMC]

99.

Uzawa A, Kawaguchi N, Kanai T, Himuro K, Kuwabara S. Serum high mobility group box 1 is upregulated in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2015;86:695–7. [DOI] [PubMed]

100.

Moser B, Bekos C, Zimprich F, Nickl S, Klepetko W, Ankersmit J. The receptor for advanced glycation endproducts and its ligands in patients with myasthenia gravis. Biochem Biophys Res Commun. 2012;420:96–101. [DOI] [PubMed]

101.

Fasshauer M, Blüher M. Adipokines in health and disease. Trends Pharmacol Sci. 2015;36:461–70. [DOI] [PubMed]

102.

Braz NFT, Rocha NP, Vieira ÉLM, Gomez RS, Kakehasi AM, Teixeira AL. Body composition and adipokines plasma levels in patients with myasthenia gravis treated with high cumulative glucocorticoid dose. J Neurol Sci. 2017;381:169–75. [DOI] [PubMed]

103.

Zhang DQ, Wang R, Li T, Li X, Qi Y, Wang J, et al. Remarkably increased resistin levels in anti-AChR antibody-positive myasthenia gravis. J Neuroimmunol. 2015;283:7–10. [DOI] [PubMed]

104.

Rasmussen LJH, Petersen JEV, Eugen-Olsen J. Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation. Front Immunol. 2021;12:780641. [DOI] [PubMed] [PMC]

105.

Uzawa A, Kojima Y, Ozawa Y, Yasuda M, Onishi Y, Akamine H, et al. Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study. Clin Exp Immunol. 2020;202:321–4. [DOI] [PubMed] [PMC]

106.

Li L, Cai D, Zhong H, Liu F, Jiang Q, Liang J, et al. Mitochondrial dynamics and biogenesis indicators may serve as potential biomarkers for diagnosis of myasthenia gravis. Exp Ther Med. 2022;23:307. [DOI] [PubMed] [PMC]

107.

Lepedda AJ, Deiana GA, Lobina O, Nieddu G, Baldinu P, De Muro P, et al. Plasma vitronectin is reduced in patients with myasthenia gravis: diagnostic and pathophysiological potential. J Circ Biomark. 2019;8:1–9. [DOI] [PubMed] [PMC]

108.

Thanner J, Bekos C, Veraar C, Janik S, Laggner M, Boehm PM, et al. Heat shock protein 90α in thymic epithelial tumors and non-thymomatous myasthenia gravis. Oncoimmunology. 2020;9:1756130. [DOI] [PubMed] [PMC]